Axis

HEALTH CENTER CLUSTER

HEALTH CENTER CLUSTER

ADVOCACY LEARNING CENTER: COMPREHENSIVE TRAINING AND TECHNICAL ASSISTANCE FOR ADVOCATES

ADVOCACY LEARNING CENTER

ADVOCACY LEARNING CENTER

NOVEL DOPAMINERGIC STIMULANT PRODRUG FOR THE TREATMENT OF APATHY IN AD

MINIMALLY INVASIVE ACCESS AND ASPIRATION OF CIRCULATING LYMPHOCYTES FROM THE THORACIC DUCT - BUILDING ON A HALF-CENTURY OF INNOVATION IN TRANSVASCULAR ACCESS AND ULTRASOUND IMAGE GUIDANCE, LXS HAS DEVELOPED A NOVEL CATHETER DEVICE AND VENOUS ACCESS PROCEDURE TO CANNULATE AND ASPIRATE THE THORACIC DUCT UNDER ULTRASOUND GUIDANCE. THE COMPANY HAS SUCCESSFULLY COMPLETED PHASE I AND II OF THE NIH’S SBIR PROGRAM AND IS APPLYING FOR A COMMERCIALIZATION READINESS PILOT (CRP) AWARD TO COMPLETE DEVELOPMENT, PREPARE AND SUBMIT FOR FDA CLEARANCE, RAMP MANUFACTURING, AND DEVELOP CRITICAL SALES AND MARKETING STRATEGIES IN ANTICIPATION OF COMMERCIAL USE. THIS CRP PROGRAM HAS FOUR SPECIFIC AIMS TO BE COMPLETED OVER THREE YEARS. WITH INTEREST IN CELL-BASED THERAPIES FOR A VARIETY OF DISEASE STATES IS AT AN ALL-TIME HIGH, ACCESS TO LARGE NUMBERS OF SUBSTRATE CELLS REMAINS A SIGNIFICANT OBSTACLE. HARVESTING RARE CELL TYPES FROM PERIPHERAL BLOOD IS COSTLY AND TIME CONSUMING. AT PRESENT, DEVELOPMENT OF LYMPHOCYTE-FOCUSED THERAPIES DEPENDS ON CELLS COLLECTED FROM PERIPHERAL BLOOD WHERE LYMPHOCYTES MAKE UP LESS THAN 3% OF CIRCULATING CELLS. THE LOW NUMBER OF DESIRABLE CELLS MAKES EX-VIVO EXPANSION AND MANIPULATION IMPOSSIBLE IN A POINT-OF-CARE SETTING. OVER A QUARTER CENTURY OF RESEARCH HAS SIGNIFICANTLY IMPROVED OUR UNDERSTANDING OF THE CIRCULATING CARDIOVASCULAR SYSTEM AND ITS CELLULAR COMPONENTS. HOWEVER, STUDY OF THE PARALLEL LYMPHATIC SYSTEM HAS LAGGED FAR BEHIND, LIMITING OUR UNDERSTANDING OF THIS COMPLEX AND POTENTIALLY CLINICAL BENEFICIAL NETWORK. THE LYMPHATIC SYSTEM IS COMPRISED OF AN EXTENSIVE NETWORK OF VESSELS AND NODES THAT PARALLEL THE VENOUS VASCULATURE. PERIPHERAL LYMPHATIC CHANNELS COMBINE TO FORM A SINGLE THORACIC DUCT THAT ENTERS THE VENOUS SYSTEM AT THE CONFLUENCE OF THE LEFT INTERNAL JUGULAR AND SUBCLAVIAN VEINS. THE LYMPHATIC SYSTEM PLAYS A NUMBER OF CRITICAL ROLES IN PATHOPHYSIOLOGICAL CONDITIONS SUCH AS DIABETES, HEART FAILURE, CANCER, AND AUTOIMMUNE DISORDERS. IN PHASE I, WE DESIGNED AND TESTED A PROOF-OF-CONCEPT DEVICE CAPABLE OF ACCESSING THE THORACIC DUCT FROM A LEFT SUBCLAVIAN VEIN APPROACH. IN PHASE II, THE COMPANY FURTHER REFINED OUR APPROACH AND VALIDATED PRE - CLINICAL DEVICES IN A LARGE ANIMAL STUDY AND A UNIQUE PERFUSED CADAVER MODEL. OUTSIDE OF NIH-FUNDED EFFORTS, THE COMPANY CONDUCTED A SUCCESSFUL FIRST-IN-HUMAN STUDY, GREW OUR IP PORTFOLIO TO 10 APPLICATIONS AND ISSUED PATENTS, AND ATTRACTED ADDITIONAL FUNDING AND RESOURCES FROM THE WELLCOME TRUST, AMFAR, AND J&J. COMPLETION OF THIS CRP PROGRAM WILL PLACE THE COMPANY IN A POSITION TO LAUNCH SALES WITH AN FDA CLEARED DEVICE AS A DIRECT COMPETITOR TO PLASMAPHERESIS AND THE ONLY TRANSVASCULAR ACCESS DEVICE FOR LYMPHOCYTE COLLECTION AND DEPLETION. NEXT, THROUGH COLLABORATIONS AND PARTNERSHIPS WITH LEADERS IN BASIC SCIENCE AND CLINICAL MEDICINE, WE PLAN TO IMPLEMENT A RANGE OF STUDIES AND APPLICATIONS TO EXPAND THE THERAPEUTIC ROLE FOR LARGE-SCALE LYMPHOCYTE COLLECTION AND MANIPULATION. DATA FROM POST-MARKET CLINICAL STUDIES IN CAR T-CELL PRODUCTION, INFECTIOUS DISEASE, HEART FAILURE, AND AUTOIMMUNE DISORDERS WILL LEAD TO ADDITIONAL INDICATION-SPECIFIC CLEARANCES.

AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS

FY 2004 OVW TECHNICAL ASSISTANCE PROGRAM

THE OFFICE ON VIOLENCE AGAINST WOMEN (OVW) TRAINING AND TECHNICAL ASSISTANCE (TA) INITIATIVE PROVIDES OVW GRANTEES AND SUBGRANTEES WITH THE EXPERTISE AND SUPPORT THEY NEED TO DEVELOP AND IMPLEMENT SUCCESSFUL STATE, LOCAL, TRIBAL, AND CAMPUS PROJECTS; INCREASE VICTIM SAFETY; AND BOLSTER OFFENDER ACCOUNTABILITY. THROUGH COOPERATIVE AGREEMENTS, OVW SUPPORTS EDUCATIONAL INITIATIVES, CONFERENCES, PEER-TO-PEER CONSULTATIONS, AND TARGETED ASSISTANCE THAT ALLOW CURRENT AND POTENTIAL GRANTEES AND SUBGRANTEES TO LEARN FROM EXPERTS AND ONE ANOTHER ABOUT HOW TO OVERCOME OBSTACLES AND INCORPORATE PROMISING PRACTICES IN THEIR EFFORTS TO ADDRESS VIOLENCE AGAINST WOMEN. IN ADDITION, OVW IS FOCUSED ON BUILDING THE CAPACITY OF THE CRIMINAL AND CIVIL JUSTICE SYSTEMS AND VICTIM SERVICE PROVIDERS TO RESPOND EFFECTIVELY TO DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING AND TO FOSTER PARTNERSHIPS BETWEEN ORGANIZATIONS THAT HAVE NOT TRADITIONALLY WORKED TOGETHER TO ADDRESS VIOLENCE AGAINST WOMEN. WITH FY 2024 TA INITIATIVE FUNDING, PRAXIS INTERNATIONAL WILL CONTINUE ITS ADVOCACY LEARNING CENTER PROJECT. THIS PROJECT WILL PROVIDE TRAINING AND TECHNICAL ASSISTANCE TO VICTIM ADVOCATES ON STRENGTHENING THEIR ABILITY TO IMPLEMENT INDIVIDUAL, COMMUNITY, AND INSTITUTIONAL SOCIAL JUSTICE ADVOCACY WITHIN THEIR GENDER-BASED VIOLENCE PROGRAMS. OVER THE COURSE OF THE PROJECT PERIOD, PRAXIS INTERNATIONAL WILL PROVIDE DIRECT TECHNICAL ASSISTANCE, HOST VIRTUAL AND IN-PERSON TRAININGS ON TOPICS SUCH AS FOUNDATIONAL SOCIAL JUSTICE ADVOCACY, WELLNESS, AND SYSTEMS-BASED ADVOCACY, CONTINUE IMPLEMENTING THE ADVANCED ADVOCACY LEARNING CENTER COURSE FOR NEW COHORTS, CONDUCT WEBINARS, AND CREATE AND/OR UPDATE RESOURCES AS NEEDED. THIS PROJECT SUPPORTS FY 2024 TA INITIATIVE: 52: COMPREHENSIVE FOR ADVOCACY. THE TIMING FOR PERFORMANCE OF THIS AWARD IS 24 MONTHS. THIS AWARD IS A CONTINUATION OF 15JOVW-22-GK-04028-MUMU. THIS AWARD IS FOR YEARS 3 AND 4 OF A FIVE-YEAR COMPREHENSIVE TA PROJECT AWARDED COMPETITIVELY UNDER THE FY 2022 TA INITIATIVE SOLICITATION.

LEAD OPTIMIZATION OF ORAL DHFR INHIBITOR FOR THE TREATMENT OF MULTIDRUG-RESISTANT N. GONORRHOEAE INFECTIONS. - ABSTRACT. THE DEVELOPMENT OF NEW ANTIBIOTICS FOR TREATING N. GONORRHOEAE (NG) IS LAGGING BEHIND THE RAPID EMERGENCE OF RESISTANT STRAINS. NG HAS DEVELOPED RESISTANCE TO ALL FDA-APPROVED THERAPIES AND EVEN TO UNAPPROVED DRUGS LIKE GEPOTIDACIN AND SOLITHROMYCIN. THIS HIGHLIGHTS THE SCARCITY OF ANTIMICROBIALS IN CLINICAL DEVELOPMENT, UNDERSCORING THE URGENT NEED TO DISCOVER NEW ANTIBACTERIAL AGENTS, IDEALLY ORAL DRUGS, THAT CAN TARGET DRUG-RESISTANT NG. THIS SBIR PHASE 2 PROPOSAL PRESENTS A SIGNIFICANT OPPORTUNITY TO DEVELOP A NARROW-SPECTRUM ORAL THERAPEUTIC FOR NG, WHERE EXISTING FIRST-LINE THERAPIES FAIL. OUR PROPRIETARY CHEMICAL CLASS TARGETS BACTERIAL DIHYDROFOLATE REDUCTASE (DHFR) AND SHOWS EXCELLENT IN VITRO POTENCY, PARTICULARLY AGAINST MDR NG CLINICAL ISOLATES. THIS CLASS ALSO BOASTS OUTSTANDING ORAL BIOAVAILABILITY, TARGET SELECTIVITY, A FAVORABLE RESISTANCE PROFILE, ACCEPTABLE TOXICITY PROFILE, VERY GOOD PHARMACOKINETIC (PK), AND PHYSICOCHEMICAL/ADME PROPERTIES. WHILE INACTIVE AGAINST OTHER GRAM-POSITIVE AND GRAM- NEGATIVE PATHOGENS, THE LEAD COMPOUNDS TXA15054 AND TXA16126 ARE POTENT AGAINST MULTIPLE NG STRAINS, INCLUDING CEFTRIAXONE-RESISTANT STRAINS (WHO-X, WHO-Y, WHO-Z), AND AZITHROMYCIN-, CIPROFLOXACIN-, AND TETRACYCLINE-RESISTANT CDC ISOLATES, WITH IMPRESSIVE LOW MIC VALUES RANGING FROM 0.031 TO 0.004 ΜG/ML. BIOCHEMICAL AND GENETIC METHODS HAVE CONFIRMED DHFR AS THE PRIMARY TARGET. TAXIS COMPOUNDS EXHIBIT NEGLIGIBLE ACTIVITY AGAINST HUMAN DHFR, WITH AN IC50 SELECTIVITY RATIO (HUMAN/NG) EXCEEDING 900-FOLD FOR BOTH LEADS. THESE COMPOUNDS ALSO HAVE MODERATE AQUEOUS SOLUBILITY, HIGH PLASMA AND METABOLIC STABILITY, AND NO CYP INHIBITION. THEIR CYTOTOXICITY AND HERG SELECTIVE WINDOW ARE SEVERAL HUNDRED-FOLD ABOVE NG MICS, INDICATING A FAVORABLE SAFETY PROFILE FOR CLINICAL USE. TXA15054 HAS EXCELLENT PK PROPERTIES AND AN ORAL BIOAVAILABILITY OF 85%. MOREOVER, TXA15054 COMPLETELY ERADICATED NG IN A MOUSE VAGINAL TRACT INFECTION MODEL FOLLOWING ORAL ADMINISTRATION, HIGHLIGHTING THE IMPORTANCE OF THIS PROPOSAL IN DEVELOPING ORAL THERAPEUTICS FOR DRUG-RESISTANT NG INFECTIONS. THIS APPLICATION AIMS TO OPTIMIZE THE LEAD CANDIDATES BY ADDRESSING THREE KEY LIABILITIES: LOW INTRINSIC SOLUBILITY, LOW THERAPEUTIC INDEX, AND MODERATE CYTOTOXICITY. LEVERAGING INSIGHTS FROM EARLY ANALOGS, THE MULTIPARAMETRIC LEAD OPTIMIZATION CAMPAIGN WILL FOCUS ON ELIMINATING THESE LIABILITIES TO PRODUCE TWO PRECLINICAL CANDIDATES. WE BELIEVE THIS SBIR GRANT WILL BOLSTER OUR EFFORTS TO DELIVER A FIRST-LINE ORAL TREATMENT FOR MULTIDRUG-RESISTANT NG INFECTIONS.

THE OFFICE ON VIOLENCE AGAINST WOMEN (OVW) TRAINING AND TECHNICAL ASSISTANCE (TA) INITIATIVE PROVIDES OVW GRANTEES AND SUBGRANTEES WITH THE EXPERTISE AND SUPPORT THEY NEED TO DEVELOP AND IMPLEMENT SUCCESSFUL STATE, LOCAL, TRIBAL, AND CAMPUS PROJECTS; INCREASE VICTIM SAFETY; AND BOLSTER OFFENDER ACCOUNTABILITY. THROUGH COOPERATIVE AGREEMENTS, OVW SUPPORTS EDUCATIONAL INITIATIVES, CONFERENCES, PEER-TO-PEER CONSULTATIONS, AND TARGETED ASSISTANCE THAT ALLOW CURRENT AND POTENTIAL GRANTEES AND SUBGRANTEES TO LEARN FROM EXPERTS AND ONE ANOTHER ABOUT HOW TO OVERCOME OBSTACLES AND INCORPORATE PROMISING PRACTICES IN THEIR EFFORTS TO ADDRESS VIOLENCE AGAINST WOMEN. IN ADDITION, OVW IS FOCUSED ON BUILDING THE CAPACITY OF THE CRIMINAL AND CIVIL JUSTICE SYSTEMS AND VICTIM SERVICES PROVIDERS TO RESPOND EFFECTIVELY TO DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING AND TO FOSTER PARTNERSHIPS BETWEEN ORGANIZATIONS THAT HAVE NOT TRADITIONALLY WORKED TOGETHER TO ADDRESS VIOLENCE AGAINST WOMEN.   THIS AWARD WILL SUPPORT FY 2022 TA INITIATIVE PURPOSE AREA 47, TO PROVIDE TRAINING AND TECHNICAL ASSISTANCE TO COMMUNITY-BASED VICTIM ADVOCATES AND ADVOCACY PROGRAMS ADDRESSING VIOLENCE AGAINST WOMEN. THE PROJECT WILL BE COMPREHENSIVE IN SCOPE, SUPPORTING ADVOCATES ACROSS OVW GRANT PROGRAMS. THE PROJECT WILL  FOCUS ON STRENGTHENING SKILLS FOR ADVOCATES IN A COORDINATED COMMUNITY RESPONSE AND IN THE LIVES OF VICTIMS. THE PROJECT WILL INCLUDE IN-PERSON AND REMOTE TRAINING AND TECHNICAL ASSISTANCE OPPORTUNITIES, AS WELL AS A FORUM FOR ADVOCATES TO LEARN FROM EACH OTHER.   THE TIMING FOR PERFORMANCE OF THIS AWARD IS 24 MONTHS.   THIS AWARD IS FOR YEARS 1 AND 2 OF A FIVE-YEAR COMPREHENSIVE TA PROJECT AWARDED COMPETITIVELY UNDER THE FY 2022 TA INITIATIVE SOLICITATION. THIS AWARD IS A CONTINUATION OF 15JOVW-21-GK-02247-MUMU.

LEAD OPTIMIZATION OF A NOVEL CYCLIC ARYL-INDOLE EFFLUX PUMP INHIBITOR (EPI) SERIES IN COMBINATION WITH LEVOFLOXACIN AGAINST PSEUDOMONAS AERUGINOSA - TREATMENT OF HOSPITAL-ACQUIRED PNEUMONIA (HAP) AND VENTILATOR-ASSOCIATED PNEUMONIA (VAP) CAUSED BY MULTIDRUG-RESISTANT (MDR) P. AERUGINOSA INFECTION REMAINS A CHALLENGE AT THE CLINIC DUE TO SUBOPTIMAL RESPONSES TO EXISTING ANTIBIOTICS. AROUND 42% OF THE 64,000 HAP CASES WITH P. AERUGINOSA INFECTION LEAD TO DEATH IN THE US ANNUALLY. MDR P. AERUGINOSA IS OFTEN ASSOCIATED WITH OVEREXPRESSION OF MULTIPLE EFFLUX PUMPS THAT LIMIT THE EXPOSURE OF SEVERAL CLASSES OF ANTIBIOTICS RENDERING THEM INEFFECTIVE. AS A COUNTERSTRATEGY, TAXIS PHARMACEUTICALS IS COMMITTED TO FINDING EFFECTIVE ANTI-PSEUDOMONAL THERAPY INVOLVING NOVEL EFFLUX PUMP INHIBITORS (EPIS) AS ADJUNCTIVE WITH LEVOFLOXACIN, TO ENHANCE ITS EXPOSURE IN GRAM-NEGATIVE PATHOGENS BY BLOCKING THEIR EFFLUX CAPABILITIES. DURING THE HIT-TO-LEAD CAMPAIGN OF THIS PROGRAM, OUR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) EFFORTS HAVE SUCCESSFULLY IDENTIFIED A 7-MEMBERED DIHYDROBENZO AZEPINOINDOLONE COMPOUND (TXA14007) AS THE LEAD EPI WITH FAVORABLE ADME AND PHYSIOCHEMICAL PROPERTIES. TXA14007 SHOWS REMARKABLE POTENTIATION OF LEVOFLOXACIN AGAINST MDR STRAINS FROM CDC AND WRAIR-MRSN COLLECTIONS AS WELL AS OTHER MDR CLINICAL ISOLATES OF P. AERUGINOSA RETRIEVED FROM 63 COUNTRIES AND 3 US HOSPITALS. MECHANISTIC STUDIES INDICATE THAT TXA14007 SPECIFICALLY INHIBITS EFFLUX PUMP ACTIVITIES, WITHOUT AFFECTING BACTERIAL MEMBRANE INTEGRITY. PREVIOUS CLINICAL DEVELOPMENT OF EPIS HAS STALLED OR STOPPED DUE TO EITHER TOXICITY CONCERNS OR LIMITED EVIDENCE FOR IN VIVO EFFICACY. IN CONTRAST, TAXIS’ TXA14007 HAS DEMONSTRATED DURABLE, VALIDATED IN VIVO EFFICACY IN MURINE LUNG INFECTION MODEL WITH WILD-TYPE P. AERUGINOSA IN COMBINATION WITH LEVOFLOXACIN. MOREOVER, TXA14007 HAS SO FAR CIRCUMVENTED THE MAJOR TOXICOLOGICAL ISSUES THAT PLAGUED PREVIOUS DEVELOPMENTAL EPIS, SHOWING A RELATIVELY SAFER TOXICOLOGY PROFILE WHEN SCREENED FOR CYTOTOXICITY, HEMOLYTIC ACTIVITY, OFF-TARGET RECEPTOR BINDING, HERG CHANNEL INHIBITION, IN VITRO NEPHROTOXICITY, AND ACUTE TOXICITY. FURTHER, A CLOSE ANALOG OF TXA14007 DISPLAYS A COMPLEMENTARY PHARMACOKINETIC PROFILE WITH LEVOFLOXACIN IN PLASMA AND BALF SAMPLES OF INFECTED MICE, THUS ENSURING MAXIMUM PHARMACODYNAMIC BENEFITS. THE GOAL OF THIS SBIR PHASE II APPLICATION IS TO OPTIMIZE TXA14007 WITH A MULTIPARAMETRIC SAR STUDY TO FURTHER IMPROVE ITS EFFICACY IN TERMS OF COMBINATION SYNERGY AND PK PARAMETERS, AS WELL AS FURTHER ADVANCING OUR INVESTIGATION INTO ITS (AND ANALOGS’) IN VIVO NEPHROTOXICITY AND CARDIOTOXICITY PROFILE. IF SUCCESSFUL, OUR PHASE II EFFORTS WILL LEAD UP TO A PRECLINICAL CANDIDATE WITH A REAL CHANCE TO REACH THE CLINIC AND SAVE LIVES.

ONLINE TRAINING FOR ADDRESSING PERINATAL DEPRESSION

ADVOCACY LEARNING CENTER

VALIDATING PRODRUG PRX-P4-003 APPROACH IN HUMANS BY PHASE 0 MICRODOSE STUDY

RISK MANAGEMENT IN DEVELOPMENTAL DISABILITES

MISSION U: A MULTIMEDIA TRAINING TOOL FOR TREATING INDIVIDUALS WITH CO-OCCURRING MENTAL HEALTH AND SUBSTANCE USE DISORDERS

EMERGENCY OPERATIONS PLANS FOR INDIVIDUALS WITH DISABILITIES

PURPOSE: THE CONTINUUM OF CARE (COC) PROGRAM IS DESIGNED TO PROMOTE COMMUNITY-WIDE COMMITMENT TO THE GOAL OF ENDING HOMELESSNESS; PROVIDE FUNDING FOR EFFORTS BY NONPROFIT PROVIDERS, STATES, AND LOCAL GOVERNMENTS TO QUICKLY HOUSE HOMELESS INDIVIDUALS AND FAMILIES WHILE MINIMIZING THE TRAUMA AND DISLOCATION CAUSED TO HOMELESS INDIVIDUALS, FAMILIES, AND COMMUNITIES BY HOMELESSNESS; PROMOTE ACCESS TO AND EFFECTIVE UTILIZATION OF MAINSTREAM PROGRAMS BY HOMELESS INDIVIDUALS AND FAMILIES; AND OPTIMIZE SELF-SUFFICIENCY AMONG INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS. THE MOST RECENT COC AWARD ANNOUNCEMENT LISTING AWARDS BY STATE AND COC IS ACCESSIBLE AT HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/COMM_PLANNING/COC/AWARDS. SELECT THE LINK UNDER THE FUNDING AND AWARD INFORMATION SECTION FOR THE APPROPRIATE FISCAL YEAR.; ACTIVITIES TO BE PERFORMED: CONTINUUM OF CARE PROGRAM FUNDS MAY BE USED TO PAY FOR THE ELIGIBLE COSTS USED TO ESTABLISH AND OPERATE PROJECTS UNDER FIVE PROGRAM COMPONENTS: (1) PERMANENT HOUSING, WHICH INCLUDES PERMANENT SUPPORTIVE HOUSING FOR PERSONS WITH DISABILITIES, AND RAPID REHOUSING; (2) TRANSITIONAL HOUSING; (3) SUPPORTIVE SERVICES ONLY; (4) HOMELESS MANAGEMENT INFORMATION SYSTEMS (HMIS), AND (5) IN SOME CASES, HOMELESSNESS PREVENTION. THIRTEEN TYPES OF ASSISTANCE MAY BE PROVIDED THROUGH THE CONTINUUM OF CARE (COC) PROGRAM: (1) COC PLANNING ACTIVITIES/COSTS FOR DESIGNING AND CARRYING OUT A COLLABORATIVE PROCESS FOR THE DEVELOPMENT OF AN APPLICATION TO HUD; (2) UNITED FUNDING AGENCY (UFA) COSTS FOR FISCAL CONTROL AND ACCOUNTING NECESSARY TO ASSURE THE PROPER DISBURSAL OF, AND ACCOUNTING FOR, FEDERAL FUNDS AWARDED TO SUBRECIPIENTS UNDER THE CONTINUUM OF CARE PROGRAM, (3) ACQUISITION OF REAL PROPERTY (INCLUDING STRUCTURES) FOR USE IN THE PROVISION OF HOUSING OR SUPPORTIVE SERVICES; (4) REHABILITATION OF STRUCTURES TO PROVIDE HOUSING OR SUPPORTIVE SERVICES; (5) NEW CONSTRUCTION, INCLUDING THE BUILDING OF A NEW STRUCTURE OR BUILDING AN ADDITION TO AN EXISTING STRUCTURE FOR USE AS SUPPORTIVE HOUSING; (6) LEASING OF A STRUCTURE OR STRUCTURES, OR PORTIONS THEREOF, TO PROVIDE HOUSING OR SUPPORTIVE SERVICES; (7) RENTAL ASSISTANCE, WHICH MAY BE SHORT-TERM, MEDIUM-TERM, OR LONG-TERM, AS WELL AS TENANT-BASED, PROJECT-BASED, OR SPONSOR-BASED, FOR TRANSITIONAL OR PERMANENT HOUSING; (8) SUPPORTIVE SERVICES TO ASSIST PROGRAM PARTICIPANTS OBTAIN AND MAINTAIN HOUSING; (9) OPERATING COSTS OF SUPPORTIVE HOUSING; (10) COSTS OF IMPLEMENTING AND OPERATING HMIS; (11) PROJECT ADMINISTRATIVE COSTS; (12) RELOCATION COSTS; AND (13) INDIRECT COSTS IN ACCORDANCE WITH 2 CFR PARTS 200, AS APPLICABLE. IN ADDITION TO USING GRANT FUNDS FOR THE ELIGIBLE COSTS DESCRIBED ABOVE, RECIPIENTS AND SUBRECIPIENTS IN CONTINUUMS OF CARE DESIGNATED AS HIGH PERFORMING COMMUNITIES MAY ALSO USE GRANT FUNDS TO PROVIDE HOUSING RELOCATION AND STABILIZATION SERVICES AND SHORT- AND/OR MEDIUM-TERM RENTAL ASSISTANCE TO INDIVIDUALS AND FAMILIES AT RISK OF HOMELESSNESS AS SET FORTH IN 24 CFR 576.103 AND 24 CFR 576.104, IF NECESSARY TO PREVENT THE INDIVIDUAL OR FAMILY FROM BECOMING HOMELESS. LIMITATION ON USE OF FUNDS: NO ASSISTANCE PROVIDED UNDER PROGRAM (OR ANY STATE OR LOCAL GOVERNMENT FUNDS USED TO SUPPLEMENT THIS ASSISTANCE) MAY BE USED TO REPLACE STATE OR LOCAL FUNDS PREVIOUSLY USED, OR DESIGNATED FOR USE, TO ASSIST HOMELESS PERSONS OR PERSONS AT-RISK OF HOMELESSNESS.; EXPECTED OUTCOMES: DECREASE IN THE NUMBER INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS, MORE SPECIFICALLY USING PERFORMANCE INDICATORS SUCH AS THE LENGTH OF TIME HOMELESS, RETURNS TO HOMELESSNESS OVER TIME, AND EXITS TO PERMANENT HOUSING. COC PERFORMANCE PROFILE REPORTS CAN BE FOUND AT HTTPS://WWW.HUDEXCHANGE.INFO/PROGRAMS/COC/COC-PERFORMANCE-PROFILE-REPORTS/.; INTENDED BENEFICIARIES: INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

RECOVERY ACT HEALTH CENTER CLUSTER PROGRAM

PURPOSE: THE CONTINUUM OF CARE (COC) PROGRAM IS DESIGNED TO PROMOTE COMMUNITY-WIDE COMMITMENT TO THE GOAL OF ENDING HOMELESSNESS; PROVIDE FUNDING FOR EFFORTS BY NONPROFIT PROVIDERS, STATES, AND LOCAL GOVERNMENTS TO QUICKLY HOUSE HOMELESS INDIVIDUALS AND FAMILIES WHILE MINIMIZING THE TRAUMA AND DISLOCATION CAUSED TO HOMELESS INDIVIDUALS, FAMILIES, AND COMMUNITIES BY HOMELESSNESS; PROMOTE ACCESS TO AND EFFECTIVE UTILIZATION OF MAINSTREAM PROGRAMS BY HOMELESS INDIVIDUALS AND FAMILIES; AND OPTIMIZE SELF-SUFFICIENCY AMONG INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS. THE MOST RECENT COC AWARD ANNOUNCEMENT LISTING AWARDS BY STATE AND COC IS ACCESSIBLE AT HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/COMM_PLANNING/COC/AWARDS. SELECT THE LINK UNDER THE FUNDING AND AWARD INFORMATION SECTION FOR THE APPROPRIATE FISCAL YEAR.; ACTIVITIES TO BE PERFORMED: CONTINUUM OF CARE PROGRAM FUNDS MAY BE USED TO PAY FOR THE ELIGIBLE COSTS USED TO ESTABLISH AND OPERATE PROJECTS UNDER FIVE PROGRAM COMPONENTS: (1) PERMANENT HOUSING, WHICH INCLUDES PERMANENT SUPPORTIVE HOUSING FOR PERSONS WITH DISABILITIES, AND RAPID REHOUSING; (2) TRANSITIONAL HOUSING; (3) SUPPORTIVE SERVICES ONLY; (4) HOMELESS MANAGEMENT INFORMATION SYSTEMS (HMIS), AND (5) IN SOME CASES, HOMELESSNESS PREVENTION. THIRTEEN TYPES OF ASSISTANCE MAY BE PROVIDED THROUGH THE CONTINUUM OF CARE (COC) PROGRAM: (1) COC PLANNING ACTIVITIES/COSTS FOR DESIGNING AND CARRYING OUT A COLLABORATIVE PROCESS FOR THE DEVELOPMENT OF AN APPLICATION TO HUD; (2) UNITED FUNDING AGENCY (UFA) COSTS FOR FISCAL CONTROL AND ACCOUNTING NECESSARY TO ASSURE THE PROPER DISBURSAL OF, AND ACCOUNTING FOR, FEDERAL FUNDS AWARDED TO SUBRECIPIENTS UNDER THE CONTINUUM OF CARE PROGRAM, (3) ACQUISITION OF REAL PROPERTY (INCLUDING STRUCTURES) FOR USE IN THE PROVISION OF HOUSING OR SUPPORTIVE SERVICES; (4) REHABILITATION OF STRUCTURES TO PROVIDE HOUSING OR SUPPORTIVE SERVICES; (5) NEW CONSTRUCTION, INCLUDING THE BUILDING OF A NEW STRUCTURE OR BUILDING AN ADDITION TO AN EXISTING STRUCTURE FOR USE AS SUPPORTIVE HOUSING; (6) LEASING OF A STRUCTURE OR STRUCTURES, OR PORTIONS THEREOF, TO PROVIDE HOUSING OR SUPPORTIVE SERVICES; (7) RENTAL ASSISTANCE, WHICH MAY BE SHORT-TERM, MEDIUM-TERM, OR LONG-TERM, AS WELL AS TENANT-BASED, PROJECT-BASED, OR SPONSOR-BASED, FOR TRANSITIONAL OR PERMANENT HOUSING; (8) SUPPORTIVE SERVICES TO ASSIST PROGRAM PARTICIPANTS OBTAIN AND MAINTAIN HOUSING; (9) OPERATING COSTS OF SUPPORTIVE HOUSING; (10) COSTS OF IMPLEMENTING AND OPERATING HMIS; (11) PROJECT ADMINISTRATIVE COSTS; (12) RELOCATION COSTS; AND (13) INDIRECT COSTS IN ACCORDANCE WITH 2 CFR PARTS 200, AS APPLICABLE. IN ADDITION TO USING GRANT FUNDS FOR THE ELIGIBLE COSTS DESCRIBED ABOVE, RECIPIENTS AND SUBRECIPIENTS IN CONTINUUMS OF CARE DESIGNATED AS HIGH PERFORMING COMMUNITIES MAY ALSO USE GRANT FUNDS TO PROVIDE HOUSING RELOCATION AND STABILIZATION SERVICES AND SHORT- AND/OR MEDIUM-TERM RENTAL ASSISTANCE TO INDIVIDUALS AND FAMILIES AT RISK OF HOMELESSNESS AS SET FORTH IN 24 CFR 576.103 AND 24 CFR 576.104, IF NECESSARY TO PREVENT THE INDIVIDUAL OR FAMILY FROM BECOMING HOMELESS. LIMITATION ON USE OF FUNDS: NO ASSISTANCE PROVIDED UNDER PROGRAM (OR ANY STATE OR LOCAL GOVERNMENT FUNDS USED TO SUPPLEMENT THIS ASSISTANCE) MAY BE USED TO REPLACE STATE OR LOCAL FUNDS PREVIOUSLY USED, OR DESIGNATED FOR USE, TO ASSIST HOMELESS PERSONS OR PERSONS AT-RISK OF HOMELESSNESS.; EXPECTED OUTCOMES: DECREASE IN THE NUMBER INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS, MORE SPECIFICALLY USING PERFORMANCE INDICATORS SUCH AS THE LENGTH OF TIME HOMELESS, RETURNS TO HOMELESSNESS OVER TIME, AND EXITS TO PERMANENT HOUSING. COC PERFORMANCE PROFILE REPORTS CAN BE FOUND AT HTTPS://WWW.HUDEXCHANGE.INFO/PROGRAMS/COC/COC-PERFORMANCE-PROFILE-REPORTS/.; INTENDED BENEFICIARIES: INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

CONTINUUM OF CARE PROGRAM

DEVELOPMENTAL DISABILITIES DENTISTRY ONLINE

PRAXIS BLUEPRINT FOR SAFETY TECHNICAL ASSISTANCE PROJECT WILL SUPPORT COMMUNITIES ACROSS THE COUNTRY TO CREATE DETERRENCE TO CRIMES OF DOMESTIC VIOLENCE BY ADOPTING THE BLUEPRINT FOR SAFETY.

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

PRAXIS INTERNATIONAL: TARGETED TECHNICAL ASSISTANCE ON SAFETY AND ACCOUNTABILITY AUDITS TO OVW GRANTEE PROGRAMS

BEHAVIORAL INTERVENTION IN AUTISM: PRACTITIONER SKILLS

RURAL ADVOCACY AND INTERAGENCY RESPONSES TO VAW COMPETITIVE TARGETED TECHNICAL ASSISTANCE TO SUPPORT RURAL PROGRAMS TO BUILD AND DEVELOP CAPACITY T

PRAXIS INTERNATIONAL: TARGETED TECHNICAL ASSISTANCE TO RURAL GRANTEE PROGRAMS FUNDED THROUGH THE OFFICE ON VIOLENCE AGAINST WOMEN FOCUS ON COORDINATE

THE OFFICE ON VIOLENCE AGAINST WOMEN (OVW) TRAINING AND TECHNICAL ASSISTANCE (TA) INITIATIVE PROVIDES OVW GRANTEES AND SUBGRANTEES WITH THE EXPERTISE AND SUPPORT THEY NEED TO DEVELOP AND IMPLEMENT SUCCESSFUL STATE, LOCAL, TRIBAL, AND CAMPUS PROJECTS; INCREASE VICTIM SAFETY; AND BOLSTER OFFENDER ACCOUNTABILITY. THROUGH COOPERATIVE AGREEMENTS, OVW SUPPORTS EDUCATIONAL INITIATIVES, CONFERENCES, PEER-TO-PEER CONSULTATIONS, AND TARGETED ASSISTANCE THAT ALLOW CURRENT AND POTENTIAL GRANTEES AND SUBGRANTEES TO LEARN FROM EXPERTS AND ONE ANOTHER ABOUT HOW TO OVERCOME OBSTACLES AND INCORPORATE PROMISING PRACTICES IN THEIR EFFORTS TO ADDRESS VIOLENCE AGAINST WOMEN. IN ADDITION, OVW IS FOCUSED ON BUILDING THE CAPACITY OF THE CRIMINAL AND CIVIL JUSTICE SYSTEMS AND VICTIM SERVICE ORGANIZATIONS TO RESPOND EFFECTIVELY TO DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING AND TO FOSTER PARTNERSHIPS BETWEEN ORGANIZATIONS THAT HAVE NOT TRADITIONALLY WORKED TOGETHER TO ADDRESS VIOLENCE AGAINST WOMEN. WITH FY 2023 TA INITIATIVE FUNDING, PRAXIS INTERNATIONAL (PRAXIS) WILL IMPLEMENT THE RURAL COMPREHENSIVE TRAINING AND TECHNICAL ASSISTANCE PROJECT. THIS PROJECT WILL PROVIDE COMPREHENSIVE TRAINING AND TECHNICAL ASSISTANCE TO GRANTEES OF THE OVW RURAL DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING PROGRAM. OVER THE COURSE OF THE PROJECT PERIOD, PRAXIS WILL PROVIDE DIRECT TECHNICAL ASSISTANCE, HOST QUARTERLY VIRTUAL SESSIONS TO CONNECT GRANTEES WITH PEERS AND SUBJECT MATTER EXPERTS AS WELL AS TO ADDRESS THE WELLBEING OF RURAL ADVOCATES, COORDINATE NEW GRANTEE ORIENTATIONS, CONDUCT VIRTUAL PEER STORYTELLING DIALOGUE SESSIONS, DEVELOP VIRTUAL AND/OR IN-PERSON TRAININGS AND INSTITUTES, DISTRIBUTE A MONTHLY NEWSLETTER, DEVELOP NEW AND/OR UPDATE PREVIOUSLY DEVELOPED MATERIALS, AND RECORD RURAL SPECIFIC PODCASTS. THIS PROJECT SUPPORTS FY 2023 TA INITIATIVE PURPOSE AREA 40: COMPREHENSIVE FOR THE RURAL DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING PROGRAM. THIS AWARD IS FOR YEARS 1 AND 2 OF A FIVE-YEAR COMPREHENSIVE TA PROJECT, AWARDED COMPETITIVELY IN FY 2023. THIS IS A NEW AWARD.

ADVOCACY LEARNING CENTER

INSTRUCTIONAL TECHNOLOGY: A PICTURE-AIDED COMMUNICATION SYSTEMS MANAGER (PACSMAN)

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

DEVELOPMENT AND VALIDATION OF NIRS-BASED SINUSITIS SCREENING

CONTINUUM OF CARE PROGRAM

FUNCTIONAL MONEY SKILLS READINESS TRAINING: TEACHING RELATIVE VALUES

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

HEALTH CENTER CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT FUNDING

HOMELESS ASSISTANCE

HOMELESS ASSISTANCE

HOMELESS ASSISTANCE

HOMELESS ASSISTANCE

HOMELESS ASSISTANCE

DEVELOPMENTAL DISABILITES EARLY INTERVENTION TRAINING

PRIORITY 6: FOOD ALLERGY AND ANAPHYLAXIS (FAA)

TARGETED TA IN ANALYZING INSTITUTIONAL RESPONSES TO VAW DESIGNED PRIMARILY FOR OVW RURAL AND ARREST GRANTEES TO ASSESS AND IMPROVE RESPONSES TO CAS

THE OFFICE ON VIOLENCE AGAINST WOMEN (OVW) TRAINING AND TECHNICAL ASSISTANCE (TA) INITIATIVE PROVIDES OVW GRANTEES AND SUBGRANTEES WITH THE EXPERTISE AND SUPPORT THEY NEED TO DEVELOP AND IMPLEMENT SUCCESSFUL STATE, LOCAL, TRIBAL, AND CAMPUS PROJECTS; INCREASE VICTIM SAFETY; AND BOLSTER OFFENDER ACCOUNTABILITY. THROUGH COOPERATIVE AGREEMENTS, OVW SUPPORTS EDUCATIONAL INITIATIVES, CONFERENCES, PEER-TO-PEER CONSULTATIONS, AND TARGETED ASSISTANCE THAT ALLOW CURRENT AND POTENTIAL GRANTEES AND SUBGRANTEES TO LEARN FROM EXPERTS AND ONE ANOTHER ABOUT HOW TO OVERCOME OBSTACLES AND INCORPORATE PROMISING PRACTICES IN THEIR EFFORTS TO ADDRESS VIOLENCE AGAINST WOMEN. IN ADDITION, OVW IS FOCUSED ON BUILDING THE CAPACITY OF THE CRIMINAL AND CIVIL JUSTICE SYSTEMS AND VICTIM SERVICE PROVIDERS TO RESPOND EFFECTIVELY TO DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING AND TO FOSTER PARTNERSHIPS BETWEEN ORGANIZATIONS THAT HAVE NOT TRADITIONALLY WORKED TOGETHER TO ADDRESS VIOLENCE AGAINST WOMEN. WITH FY 2024 TA INITIATIVE FUNDING, PRAXIS INTERNATIONAL WILL CONTINUE ITS STRENGTHENING RURAL ADVOCACY (SRA) PROJECT. THIS PROJECT WILL PROVIDE TRAINING AND INTENSIVE TECHNICAL ASSISTANCE TO GRANTEES, SUBGRANTEES, AND POTENTIAL GRANTEES AND SUBGRANTEES OF THE OVW RURAL DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING PROGRAM (RURAL PROGRAM) TO MORE EFFECTIVELY RESPOND TO DOMESTIC VIOLENCE. OVER THE COURSE OF THE PROJECT PERIOD, PRAXIS WILL PROVIDE DIRECT AND ON-GOING TECHNICAL ASSISTANCE AND IN-PERSON AND VIRTUAL TRAINING, AS WELL AS CONVENE FOCUS GROUPS AND LISTENING SESSIONS FOR OVW RURAL PROGRAM GRANTEES, SUBGRANTEES, AND POTENTIAL GRANTEES AND SUBGRANTEES. THIS PROJECT SUPPORTS FY 2024 TA INITIATIVE PURPOSE AREA 23: RURAL DOMESTIC VIOLENCE SERVICES. THE TIMING FOR PERFORMANCE OF THIS AWARD IS 36 MONTHS. THIS AWARD IS A CONTINUATION OF 2020-TA-AX-K031.

FY 2006 OFFICE ON VIOLENCE AGAINST WOMEN TECHNICAL ASSISTANCE BRIDGE AWARDS

STRENGTHENING RURAL ADVOCACY TRAINING & TECHNICAL ASSISTANCE PROJECT

HEALTH CENTER INFRASTRUCTURE SUPPORT

VISITATION TECHNICAL ASSISTANCE PROJECT

BLUEPRINT FOR SAFETY

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

EDUCATING PARENTS: BEHAVIORAL INTERVENTION IN AUTISM

CONTINUUM OF CARE PROGRAM

PRAXIS INTERNATIONAL: COMPREHENSIVE TRAINING AND TECHNICAL ASSISTANCE TO RURAL GRANTEE PROGRAMS FUNDED THROUGH THE OFFICE ON VIOLENCE AGAINST WOMEN

THE OFFICE ON VIOLENCE AGAINST WOMEN (OVW) TRAINING AND TECHNICAL ASSISTANCE (TA) INITIATIVE PROVIDES OVW GRANTEES AND SUBGRANTEES WITH THE EXPERTISE AND SUPPORT THEY NEED TO DEVELOP AND IMPLEMENT SUCCESSFUL STATE, LOCAL, TRIBAL, AND CAMPUS PROJECTS; INCREASE VICTIM SAFETY; AND BOLSTER OFFENDER ACCOUNTABILITY. THROUGH COOPERATIVE AGREEMENTS, OVW SUPPORTS EDUCATIONAL INITIATIVES, CONFERENCES, PEER-TO-PEER CONSULTATIONS, AND TARGETED ASSISTANCE THAT ALLOW CURRENT AND POTENTIAL GRANTEES AND SUBGRANTEES TO LEARN FROM EXPERTS AND ONE ANOTHER ABOUT HOW TO OVERCOME OBSTACLES AND INCORPORATE PROMISING PRACTICES IN THEIR EFFORTS TO ADDRESS VIOLENCE AGAINST WOMEN. IN ADDITION, OVW IS FOCUSED ON BUILDING THE CAPACITY OF THE CRIMINAL AND CIVIL JUSTICE SYSTEMS AND VICTIM SERVICE PROVIDERS TO RESPOND EFFECTIVELY TO DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING AND TO FOSTER PARTNERSHIPS BETWEEN ORGANIZATIONS THAT HAVE NOT TRADITIONALLY WORKED TOGETHER TO ADDRESS VIOLENCE AGAINST WOMEN. WITH FY 2024 TA INITIATIVE FUNDING, PRAXIS INTERNATIONAL WILL DEVELOP THERURAL INITIATIVES FOR STRENGTHENING EQUITY (RISE) PROJECT TOPROVIDE TA TO OVW RURAL GRANTEES, SUBGRANTEES, AND POTENTIAL GRANTEES AND SUBGRANTEES TO ASSIST THEM IN EFFECTIVELY RESPONDING TOUNDERSERVED RURALSURVIVORS. THIS PROJECT WILL SUPPORT ADVOCATES AND MENTAL HEALTH PROVIDERS TODEVELOP AND IMPLEMENT KNOWLEDGE, SKILLS, AND PRACTICES DESIGNED TOSTRENGTHEN THE CAPACITY OF OVW RURAL GRANTEES. OVER THE COURSE OF THE PROJECT PERIOD, PRAXIS WILL PROVIDE DIRECT TECHNICAL ASSISTANCE AND CONVENE VIRTUAL LISTENING SESSIONS, FOCUS GROUPS, IN-PERSON AND VIRTUAL TRAININGS, WEBINARS AND A SYMPOSIUM. THIS PROJECT SUPPORTS FY 2024 TA INITIATIVE PURPOSE AREA #24: TTA FOR RURAL GRANTEES SERVING UNDERSERVED COMMUNITIES. THE TIMING FOR PERFORMANCE OF THIS AWARD IS 24 MONTHS. THIS IS A NEW AWARD.

NOVEL TECHNOLOGIES FOR CELLULAR AGE PROFILING AND VALIDATION - PROJECT SUMMARY OBJECTIVE. THIS PROJECT AIMS TO ADDRESS A CRITICAL CHALLENGE IN BIOMEDICAL RESEARCH – THE RELIABLE IDENTIFICATION OF CELL LINE AGE AND DIVISION/PASSAGE HISTORY. LEVERAGING RECENT ADVANCES IN SYNTHETIC BIOLOGY AND GENOME EDITING, WE PROPOSE THE DEVELOPMENT OF AN INNOVATIVE TECHNOLOGY USING GENETIC PUFS, A NOVEL CONCEPT INSPIRED BY THE SEMICONDUCTOR INDUSTRY, FOR PRECISE QUANTIFICATION OF CELLULAR AGE. OUR TECHNOLOGY IS EXPECTED TO SIGNIFICANTLY ENHANCE THE REPRODUCIBILITY AND RELIABILITY OF EXPERIMENTAL OUTCOMES IN BIOMEDICAL RESEARCH. TODAY THERE ARE NO COMMERCIALLY AVAILABLE METHODS TO CALCULATE AND ATTEST CELLULAR AGE. METHODS SUCH AS SIMPLE PASSAGE TRACKING ARE NOT STANDARDIZED ACROSS LABS AND CAN BE PRONE TO ERRORS OR MISLABELING. MOREOVER, STR PROFILING, WHILE EFFECTIVE FOR CONFIRMING CELL LINE IDENTITY (BUT NOT CLONALITY), DOES NOT PROVIDE INFORMATION ABOUT PASSAGE HISTORY OR GENOMIC DRIFT THAT ARISE FROM AGING. SPECIFIC AIMS: DEVELOPMENT OF GENETIC PUFS. UTILIZING A COMBINATION OF MOLECULAR BARCODING AND CRISPR-INDUCED DNA REPAIR MECHANISMS, WE WILL EMBED UNIQUE, ROBUST, AND UNCLONABLE GENETIC IDENTIFIERS WITHIN CELL LINES. THIS WILL ALLOW FOR ACCURATE TRACKING OF CELL LINE PROVENANCE AND AGE, ENSURING THE INTEGRITY OF BIOMEDICAL EXPERIMENTS. ESTABLISHING A CELLULAR CLOCK. BY CHARACTERIZING THE TEMPORAL DRIFT SPACE OF GENETIC PUFS AND EMPLOYING ADVANCED MACHINE LEARNING ALGORITHMS, WE WILL DEVELOP A CELLULAR CLOCK . THIS CLOCK WILL PROVIDE A STANDARDIZED METHOD TO MONITOR AND RECORD CRITICAL CELLULAR EVENTS AND DIVISIONS, THEREBY ACCURATELY DETERMINING THE BIOLOGICAL AGE OF CELL LINES. HEALTH RELATEDNESS. THE PROPOSED TECHNOLOGY DIRECTLY ADDRESSES THE PERVASIVE ISSUE OF CELL LINE MISIDENTIFICATION AND CONTAMINATION IN BIOMEDICAL RESEARCH. BY ENSURING THE AUTHENTICITY AND AGE OF CELL LINES, OUR INNOVATION WILL CONTRIBUTE TO MORE ACCURATE AND RELIABLE RESEARCH OUTCOMES, ULTIMATELY BENEFITING HEALTH- RELATED STUDIES AND PHARMACEUTICAL DEVELOPMENTS. RESEARCH DESIGN AND METHODS. OUR APPROACH INTEGRATES CUTTING-EDGE GENOME EDITING TECHNIQUES AND COMPUTATIONAL METHODOLOGIES. OUR FIRST AIM WILL FOCUS ON THE CREATION AND CHARACTERIZATION OF GENETIC PUFS IN A VARIETY OF CELL LINES OVER MULTIPLE DIVISIONS/PASSAGES. OUR SECOND AIM WILL EXTEND THESE FINDINGS TO DEVELOP A COMPREHENSIVE PLATFORM FOR CELLULAR AGE IDENTIFICATION, INTEGRATING MACHINE LEARNING MODELS FOR PREDICTING AND VALIDATING THE AGE OF PUFED CELL LINES. WE WILL CONDUCT RIGOROUS TESTING AND VALIDATION ACROSS DIFFERENT CELL LINES AND CONDITIONS TO ENSURE THE ROBUSTNESS AND APPLICABILITY OF OUR TECHNOLOGY. IMPACT. THE SUCCESSFUL COMPLETION OF THE PROPOSED WORK WILL BE A SIGNIFICANT CONTRIBUTION TO THE FIELD OF CELL LINE AUTHENTICATION, PAVING THE WAY FOR MORE RELIABLE AND REPRODUCIBLE BIOMEDICAL RESEARCH. OUR TECHNOLOGY HAS THE POTENTIAL TO ENHANCE THE QUALITY AND RELIABILITY OF BIOMEDICAL RESEARCH AND TO BECOME A STANDARD TOOL IN LABS WORLDWIDE.

PROVENANCE ATTESTATION OF HUMAN CELLS USING PHYSICAL UNCLONABLE FUNCTIONS - PROJECT SUMMARY THE USE OF CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR) TECHNOLOGIES HAS SPURRED MYRIADS OF APPLICATIONS CRITICALLY RELEVANT TO HUMAN HEALTH AND, PERTINENT TO THE TOPIC OF THIS PROJECT, AN ECOSYSTEM OF COMPANIES, UNIVERSITIES, AND GOVERNMENTAL LABORATORIES THAT EITHER OFFER OR ARE IN NEED OF CUSTOM CRISPR-BASED CELL LINE ENGINEERING HAS STARTED TO EMERGE. FORESEEABLY, IN THE NEAR FUTURE, FOR EACH CELL LINE MODEL THERE WILL EXIST HUNDREDS OF CUSTOMIZED VERSIONS, EACH REQUIRING RESEARCH AND DEVELOPMENT INVESTMENT ON BEHALF OF THE PRODUCER AND CONSTITUTING A VALUABLE ASSET ON BEHALF OF THE USER. CONSIDERING THE SIGNIFICANCE OF THE MEDICAL AND BIOMEDICAL APPLICATIONS WHEREIN SUCH CELL LINES ARE USED, AS WELL AS THE IMPORTANCE OF ENSURING ACCURACY AND REPRODUCIBILITY OF THE CORRESPONDING RESULTS, THIS ECOSYSTEM COULD BENEFIT FROM MECHANISMS WHICH CAN PROTECT THE INTELLECTUAL PROPERTY ASSOCIATED WITH THE PRODUCTION OF CUSTOM ENGINEERED CELL LINES AND CAN ENSURE THEIR QUALITY. UNFORTUNATELY, EFFECTIVE CELL LINE PROVENANCE ATTESTATION SOLUTIONS ARE NOT CURRENTLY AVAILABLE IN THIS ECOSYSTEM. BESIDES LIMITING THE ABILITY OF CELL LINE PRODUCERS TO CAPITALIZE ON THEIR INVESTMENT, LACK OF SUCH SOLUTIONS ALSO RESULTS IN NUMEROUS CELL LINE ISSUES INCLUDING CROSS- CONTAMINATION, MISIDENTIFICATION, AND PROCUREMENT FROM DUBIOUS OR UNDOCUMENTED SOURCES, WHICH IN TURN UNDERMINE ROBUSTNESS, REPEATABILITY AND, ULTIMATELY, OVERALL EFFICIENCY OF MEDICAL RESEARCH. TO FILL THIS VOID, HEREIN WE FOCUS ON ONE OF THE MOST FUNDAMENTAL SECURITY PRIMITIVES WHICH CAN SUPPORT INTEGRITY AND ACCOUNTABILITY OF CELL LINE PROCUREMENT, NAMELY THE ABILITY TO ASSOCIATE A UNIQUE, ROBUST AND UNCLONABLE IDENTIFIER WITH EACH TRANSACTED PRODUCT. HEREIN, SYNTAXISBIO AND ITS RESEARCH PARTNER THE UNIVERSITY OF TEXAS AT DALLAS (UTD) AIM TO DEVELOP AND VALIDATE A TECHNOLOGY THAT WILL ENABLE PROVENANCE ATTESTATION PROTOCOLS TO INTRODUCE ACCOUNTABILITY IN CELL LINE DISTRIBUTION NETWORKS. THE PATENT-PENDING TECHNOLOGY TERMED GENETIC PHYSICAL UNCLONABLE FUNCTIONS (PUFS) WAS RECENTLY DEVELOPED IN UTD (TO APPEAR IN SCIENCE ADVANCES) AND IS USED TO INTRODUCE A UNIQUE, ROBUST AND UNCLONABLE IDENTIFIER IN CELLS. WE POSIT THAT GENETIC PUFS CAN ENABLE A PROVENANCE ATTESTATION PROTOCOL WHICH CAN BE USED NOT ONLY FOR PROTECTING THE INTELLECTUAL PROPERTY OF A CELL LINE PRODUCER BUT ALSO FOR BOLSTERING THE CONFIDENCE OF A CUSTOMER IN THE SOURCE AND, THEREBY, THE QUALITY OF A PROCURED CELL LINE. SPECIFICALLY, THE GENETIC PUF TECHNOLOGY ENABLES THE PRODUCER OF A VALUABLE CELL LINE TO INSERT A UNIQUE, ROBUST AND UNCLONABLE SIGNATURE IN EACH LEGITIMATELY PRODUCED AND AUTHENTICATED COPY OF A CELL LINE. THE PRODUCER OF THE CELL LINE CAN ENSURE THAT ANYONE WHO PUBLICLY CLAIMS OWNERSHIP OR USAGE OF A COPY OF THIS CELL LINE HAS ACQUIRED IT LEGITIMATELY. AT THE SAME TIME, THE USER OF THE CELL LINE CAN BE ASSURED OF ITS SOURCE AND QUALITY, AS THE PRODUCER EXPLICITLY CONFIRMS ITS ORIGIN AND ASSUMES RESPONSIBILITY FOR ITS PRODUCTION.

PRAXIS BEHAVIORAL OBSERVATION SOFTWARE

ISOLATION AND CHARACTERIZATION OF A PRIMARY BREAST EPITHELIUM TRANSFORMING AGENT

FY 2020 EXPANDING CAPACITY FOR CORONAVIRUS TESTING (ECT)

EMERGENCY OPERATIONS PLANS FOR INDIVIDUALS WITH DISABILITIES

EFFECT OF FLOW LAMINATION DEVICE ON AEROSOLIZED DRUG DELIVERY CHARACTERISTICS - THE RESPIRATORY TRACT IS ONE OF THE MOST ATTRACTIVE PATHWAYS FOR DELIVERING AEROSOLIZED MEDICATIONS BOTH TO THE LUNGS AND TO SYSTEMIC CIRCULATION. IT IS THE FASTEST, IT'S DEVOID OF DRUG EFFLUX TRANSPORTERS AND METABOLIZING ENZYMES, IT HAS A HUGE ALVEOLAR SURFACE AREA (700 SQUARE FEET) AND A VERY THIN MUCOSAL BARRIER AT ALVEOLAR LEVEL (0.1 MM), AND IT IS PERFUSED BY 100% OF CARDIAC OUTPUT UNLIKE ANY OTHER ORGAN OR SYSTEM. HOWEVER THERE ARE SERIOUS CHALLENGES TO EFFICIENT DELIVERY TO THE LOWER LUNGS AND TO TAKING ADVANTAGE OF THE LARGE ALVEOLAR SURFACE AREA. UP TO 80% OF THE MEDICATION MAY BE DEPOSITED IN THE UPPER AIRWAYS, MOST OF IT IN THE OROPHARYNGEAL AREA, CAUSING SIDE EFFECTS AND WASTE, AND MAKING THE DELIVERY TO TARGET AREAS UNPREDICTABLE, INEFFICIENT, AND EVEN UNRELIABLE. THEREFORE OVERCOMING THE UPPER AIRWAY BARRIERS SUCH AS OROPHARYNX IS IMPORTANT FOR MORE EFFICIENT DRUG DELIVERY TO THE LOWER LUNGS. AMONG MANY FACTORS INVOLVED IN THIS PROCESS, INERTIAL IMPACTION, TURBULENT MIXING AND INTERCEPTION ARE ESPECIALLY SIGNIFICANT IN UPPER AIRWAYS. AND A SINGLE FACTOR THAT CAN HAVE AN IMPACT ON ALL 3 OF THEM IS THE TURBULENCE IN THE OUTFLOW OF THE AEROSOL DELIVERY DEVICE, WHICH HAS NOT BEEN STUDIED SUFFICIENTLY AS AN INDEPENDENT FACTOR. IN OUR PREVIOUS STUDY MODIFLOW HAS BEEN SHOWN TO REDUCE TURBULENCE IN THE INCOMING FLOW, AND TO IMPROVE THE EFFICIENCY OF AEROSOL DELIVERY TO DISTANT TARGETS. THE OBJECTIVES OF THE PROPOSED STUDY ARE TO TEST THE ABILITY OF MODIFLOW TO IMPROVE THE DELIVERY OF AEROSOLIZED DRUGS ACROSS A SPATIAL BARRIER IMITATION OF THE OROPHARYNX. OBJECTIVE 1: TO TEST THE ABILITY OF LAMINATED FLOW FROM MODIFLOW TO IMPROVE THE DELIVERY OF AEROSOLIZED FLUTICASONE TO 3D MUCOSAL TISSUE MODELS PLACED WITHIN A BARRIER IMITATION. OBJECTIVE 2: TO MANIPULATE THE MODIFLOW GEOMETRY TO ACHIEVE THE BEST AEROSOL FLOW CHARACTERISTICS AT THE EXIT OF THE BARRIER IMITATION. THE BARRIER IMITATION IS DESIGNED TO MIMIC TWO MAIN CHARACTERISTICS OF THE OROPHARYNGEAL BARRIER IN THE AIRWAYS – NARROWING AND CURVING. BY STRATEGICALLY PLACING 3D MUCOSAL TISSUE MODELS AT THE POINT OF NARROWING AND AT THE END OF CURVING, AND BY MEASURING THE MEDICATION DEPOSITION ON THEM, WE'LL BE ABLE TO DRAW CONCLUSIONS ABOUT THE EFFECTS OF FLOW LAMINATION ON OVERCOMING THESE TYPES OF BARRIERS. AT THE SAME TIME, DETAILED CHARACTERIZATION OF AEROSOL OUTFLOW FROM THE DISTAL END OF THE BARRIER IMITATION WILL POUR LIGHT ON THE EFFECTS OF MODIFLOW GEOMETRY ON IT, PROVIDING VALUABLE INFORMATION FOR IMPROVING THOSE EFFECTS. THE OUTCOMES OF THE PROPOSED STUDY WILL HELP BETTER UNDERSTAND THE EFFECTS OF TURBULENCE IN THE DEVICE OUTFLOW ON THE EFFICIENCY OF AEROSOL DELIVERY ACROSS UPPER AIRWAY BARRIERS TO THE LOWER LUNGS.

ONLINE PRACTITIONER TRAINING IN BEHAVIORAL INTERVENTION IN AUTISM: SKILL TRAINING USING AN INTERACTIVE SIMULATED CHILD

ARRA - CAPITAL IMPROVEMENT PROGRAM

CONTINUATION OF THE BLUEPRINT FOR SAFETY ADAPTATION DEMONSTRATION PROJECT

MISSION U: A MULTIMEDIA TRAINING TOOL FOR TREATING INDIVIDUALS WITH CO-OCCURRING MENTAL HEALTH AND SUBSTANCE USE DISORDERS

ONLINE TRAINING FOR ADDRESSING PERINATAL DEPRESSION

ANTIANGIOGENIC AND ANTITUMORAL THERAPY DELIVERED BY A DUAL-EXPRESSION L. MONOCYTO

RAPID CIRCUIT-LEVEL DENDRITIC SPINE MORPHOMETRIC ANALYSIS FOR IN VIVO PHARMACOLOGY IN CNS DRUG DISCOVERY

FY 2023 EXPANDING COVID-19 VACCINATION

DEVELOPMENT OF MINIMALLY-INVASIVE CARTILAGE RESHAPING DEVICE

PURPOSE: TO SUPPORT PERSONNEL AND FACILITIES EXPENSES IN RESPONSE TO AND RECOVERY FROM THE COVID-19 PANDEMIC.

SET2READ-AK (ALPHABET KNOWLEDGE)

IOWA FOOD ALLERGY EDUCATION PROGRAM

ARRA - INCREASE SERVICES TO HEALTH CENTERS

HEARTLAND INFRASTRUCTURE DEVELOPMENT BANK

TO SUPPORT POST-PRODUCTION COSTS FOR "POOR CONSUELO CONQUERS THE WORLD " A DOCUMENTARY FILM BY PETER FRIEDMAN.

FY 2020 CORONAVIRUS SUPPLEMENTAL FUNDING FOR HEALTH CENTERS

THE LAUNCH OF NICER BRINGS UNPRECEDENTED CAPABILITIES FOR OBSERVING MAGNETIC CATACLYSMIC VARIABLES ( POLARS'). QUASI-PERIODIC OSCILLATIONS (QPOS) OF 1-3 S HAVE BEEN OBSERVED WITH FAST OPTICAL PHOTOMETRY. EXISTING HYDRODYNAMIC MODELS OF THE ACCRET

TO SUPPORT PERSONNEL COSTS IN RESPONSE TO THE COVID-19 PANDEMIC.

NICER BRINGS CAPABILITY TO RESOLVE A LONGSTANDING QUESTION IN HYDRODYNAMICS OF ACCRETING PULSARS NAMELY WHETHER THERE OCCURS THE PHOTO-HYDRODYNAMIC PHENOMENON KNOWN AS PHOTON BUBBLES WHEREIN REGIONS OF HIGH RADIATION DENSITY FORM IN THE ACCRETION CO

PURPOSE: TO SUPPORT AXISS NATIONAL TOUR OF DANCE PERFORMANCES AND ENGAGEMENT ACTIVITIES.

FY 2023 BRIDGE ACCESS PROGRAM

PURPOSE: TO SUPPORT STAFF SALARIES AND ARTIST FEES FOR A NATIONAL TOUR OF DANCE PERFORMANCES AND ENGAGEMENT ACTIVITIES.

PURPOSE: TO SUPPORT A SERIES OF ACCESSIBILITY TRAINING WORKSHOPS FOR PERFORMING ARTS VENUES AND PRESENTERS.

PURPOSE: TO SUPPORT STAFF SALARIES AND ARTIST FEES FOR A NATIONAL TOUR OF DANCE PERFORMANCES WITH ACCOMPANYING ENGAGEMENT ACTIVITIES.

TO SUPPORT A NATIONAL TOUR OF DANCE PERFORMANCES AND ENGAGEMENT ACTIVITIES.

PURPOSE: TO SUPPORT A NATIONAL TOUR OF DANCE PERFORMANCES AND ENGAGEMENT ACTIVITIES.

TO SUPPORT A NATIONAL TOUR OF DANCE PERFORMANCES AND VIRTUAL ENGAGEMENT ACTIVITIES.

TO SUPPORT DANCE EDUCATION AND OUTREACH PROGRAMS FOR YOUTH AND ADULTS WITH AND WITHOUT DISABILITIES.

TO SUPPORT DANCE ACCESS EDUCATION AND OUTREACH PROGRAMS.

TO SUPPORT DANCE ACCESS EDUCATION AND OUTREACH PROGRAMS IN THE BAY AREA AND ON A NATIONAL TOUR.

TO SUPPORT DANCE ACCESS AND DANCE/ACCESS KIDS! EDUCATIONAL AND OUTREACH PROGRAMS IN THE BAY AREA AND ON A NATIONAL TOUR.

TO SUPPORT DANCE ACCESS AND DANCE ACCESS/KIDS! EDUCATIONAL AND OUTREACH PROGRAMS IN THE BAY AREA AND ON A NATIONAL TOUR.

TO SUPPORT DANCE ACCESS AND DANCE/ACCESS KIDS! EDUCATION AND OUTREACH PROGRAMS.

TO SUPPORT DANCE ACCESS & DANCE ACCESS/KIDS! EDUCATION AND OUTREACH PROGRAMS.

TO SUPPORT THE CREATION OF A NEW WORK TITLED "FULL OF WORDS," CHOREOGRAPHED BY MARC BREW, IN CONSORTIUM WITH VERY SPECIAL ARTS OF NEW MEXICO.

TO SUPPORT DANCE ACCESS & DANCE ACCESS/KIDS! EDUCATION AND OUTREACH PROGRAMS.

TO SUPPORT THE CREATION AND PRESENTATION OF A NEW WORK BY CHOREOGRAPHER SHINICHI IOVA- KOGA AND COMPOSER/CELLIST JOAN JEANRENAUD IN CONSORTIUM WITH

TO SUPPORT DANCE ACCESS & DANCE ACCESS/KIDS! EDUCATION AND OUTREACH PROGRAMS.

TO SUPPORT DANCE EDUCATION AND OUTREACH PROGRAMS FOR YOUTH AND ADULTS WITH AND WITHOUT DISABILITIES AND THE COMPANYS PERFORMANCE ENGAGEMENTS.

TO BUY 200 SEATS FOR THE MATINEE SHOWING OF THE AMERICAN PLAY "NO CHILD..." WHICH WILL BE SHOWNTO 200 IRISH STUDENTS FROM THE LOCAL SECONDARY SCHOOL

HOMELESS ASSISTANCE